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D1 dopamine receptor signaling involves caveolin-2 in HEK-
293 cells.
Background. Dopamine receptors in the kidney, especially
those belonging to the D1-like receptor family, are important in
the regulation of renal function and blood pressure. Because of
increasing evidence that G protein-coupled receptors (GPCRs)
are associated with caveolae and lipid rafts, we tested the hy-
pothesis that the D1 dopamine receptor (D1R) and signaling
molecules are regulated by caveolin in caveolae or lipid rafts.
Methods. Six experimental approaches were used: (1) con-
struction of tagged human D1Rs (hD1Rs) and transfectants;
(2) cell culture [human embryonic kidney (HEK)-293 and im-
mortalized rat renal proximal tubule cells] and biotinylation;
(3) cell fractionation by sucrose gradient centrifugation; (4)
immunoprecipitation and immunoblotting; (5) immunofluores-
cence and confocal microscopy; and (6) adenylyl cyclase assays.
Results. hD1Rs, heterologously expressed in HEK-293 cells,
formed protein species with molecular mass ranging from 50
to 250 kD, and were localized in lipid rafts and nonraft plasma
membranes. The hD1Rs cofractionated with caveolin-2, G pro-
tein subunits, and several signaling molecules. Both exoge-
nously expressed hD1Rs and endogenously expressed rat D1Rs
colocalized and coimmunoprecipitated with caveolin-2. A D1R
agonist (fenoldopam) increased the amount of caveolin-2b as-
sociated with hD1Rs and activated adenylyl cyclase to a greater
extent in lipid rafts than in nonraft plasma membranes. Re-
duction in the expression of caveolin-2 with antisense oligonu-
cleotides attenuated the stimulatory effect of fenoldopam on
cyclic adenosine monophosphate (cAMP) accumulation.
Conclusion. The majority of hD1Rs are distributed in lipid
rafts. Heterologously and endogenously expressed D1Rs in re-
nal cells are associated with and regulated by caveolin-2.
Lipid rafts are membrane microdomains composed of
sphingolipids, cholesterol, glycolipids, and specific pro-
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teins that are characterized by their relative insolubility
in nonionic detergents at 4◦C, and light buoyant density
on sucrose gradients [1, 2]. Many types of lipid rafts have
been described and the best characterized subset of lipid
rafts is caveolae, which localize on cell surface invagina-
tions formed by polymerization of caveolin with choles-
terol [2–6]. In cells that do not express caveolin and lack
caveolae, lipid containing domains in the light buoyant
fractions on sucrose gradients have been termed non-
caveolar rafts [2, 3].
Three distinct caveolin genes encoding different sub-
types of caveolin have been identified: caveolin-1, -2, and
-3 with molecular weights of 22, 20, and 18 kD, respec-
tively [7–12]. Caveolin-1 (22 kD), the first protein to be
identified as a caveolar “coat,” is abundantly expressed
in adipocytes, endothelial cells, and fibroblasts [7–9]. The
tissue distribution of caveolin-2 closely resembles those
noted for caveolin-1 [10], whereas caveolin-3 is muscle-
specific [11, 12].
Many signaling proteins have been found in caveo-
lae and lipid rafts, including heterotrimeric G-proteins
(GaS, Ga i, and Gbc subunits), Ras-related guanosine
triphosphatases (GTPases), G protein-coupled receptor
(GPCR) kinases (GRKs), adenylyl cyclases, phospholi-
pase C, Src-like kinases, protein kinase C (PKC), protein
kinase A (PKA), and ion channels [6, 13–18]. Several
GPCRs are regulated in caveolae and noncaveolar lipid
rafts [6, 19–30]. Endothelin type A [19], B1 and B2
bradykinin [20–22], and calcium sensing [23] receptors
have been associated with caveolin-1, while A1 adeno-
sine [24, 25], b 1 and b 2 adrenergic [26–28], and type 2
muscarinic acetylcholine [29] receptors have been asso-
ciated with caveolin-3. Gonadotropin-releasing hormone
receptor has been associated with noncaveolar lipid rafts
[30]. Caveolae and other lipid rafts have been proposed
to serve as platforms for the formation of complexes
during signal transduction [1–6]. They may also serve
as compartments for the recruitment of cell signaling
components, such as adaptors, scaffolds, and enzymes, to
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increase the efficient and rapid coupling of receptors to
more than one effector system [4]. In contrast, the translo-
cation of A1 adenosine receptors out of caveolae has been
suggested as the mechanism for the few direct effects of
A1 adenosine receptors in ventricular myocytes [24].
The two major pathways for GPCR clustering and
internalization involve either clathrin-coated pits or
caveolae-coated plasmalemmal vesicles [31–34]. Human
type 2 muscarinic acetylcholine and b 2-adrenergic re-
ceptors internalize via clathrin-coated vesicles while
others internalize via nonclathrin-coated, possibly
caveolin-coated, vesicles [29, 34]. For example, B2
bradykinin receptor-mediated sequestration involves
caveolae and lipid rafts, independent of b-arrestin and
clathrin [20, 22].
Dopamine is now recognized as an important reg-
ulator of fluid and electrolyte balance by actions
on renal hemodynamics, epithelial ion transport, and
hormones and humoral agents such as aldosterone,
angiotensin II, catecholamines, endothelin, prolactin,
pro-opiomelanocortin, renin, and vasopressin [35].
Dopamine exerts its actions via two families of cell sur-
face GPCRs: D1-like receptors (D1 and D5) and D2-like
receptors (D2, D3, and D4) [35, 36]. Occupation of D1-
like receptors, via GaS, stimulates adenylyl cyclase, lead-
ing to the production of cyclic adenosine monophosphate
(cAMP) and activation of PKA. GRKs are also activated,
resulting in the phosphorylation, desensitization, and in-
ternalization of D1Rs, like other GPCRs [37–43].
The internalization of the D1R endogenously ex-
pressed in human renal proximal tubule cells or het-
erologously expressed in human embryonic kidney
(HEK)-293 cells, occurs via GRK/clathrin-dependent
and -independent pathways [38–43]. It is possible that
the clathrin-independent regulation of D1-like receptors
in renal proximal tubule cells may involve caveolae or
other lipid rafts. Although caveolin-1 and caveolin-2 have
been described in Madin-Darby canine kidney (MDCK),
a canine distal renal tubule line [13, 44, 45] and LLC-
PK1, a porcine renal tubule cell line with distal and prox-
imal tubule cell characteristics [25], neither caveolae nor
caveolin-1 has been found in rat [46] and human (un-
published studies) renal proximal tubules. We now re-
port the membrane distribution and regulation of hD1Rs
by caveolin-2. In HEK-293 cells heterologously express-
ing hD1Rs, the majority of the hD1R resides in lipid
rafts, where it colocalizes and coimmunoprecipitates with
caveolin-2, specifically caveolin-2b . D1Rs endogenously
expressed in rat renal proximal tubule cells (RPTC) also
colocalize and coimmunoprecipitate with caveolin-2. A
D1R agonist (fenoldopam) stimulates adenylyl cyclase
activity to a greater extent in low density than in high
density membrane fractions. Moreover, the fenoldopam-
mediated increase in cAMP activity is attenuated when
caveolin-2 expression is decreased. We propose that
caveolin-2 is an important regulator of hD1R function
in kidney cells.
METHODS
Materials
Reagents were obtained from the following sources:
caveolin-1 and -2–positive controls, anticaveolin-1,
anticaveolin-2, antiflotillin-1 and -2, anti-PKAc, anti-
PKARIIb , and anti-PP2A-B56a monoclonal antibodies
(BD Biosciences-Transduction Labs., Lexington, KY,
USA); anticaveolin-2 polyclonal antibody (Affinity
BioReagents Inc., Golden, CO, USA); anti-GRK2,
anti-GaS, anti-Gb common, anti-His monoclonal antibod-
ies, and protein G beads (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA); anti-myc monoclonal
antibody and lipofectamine (Invitrogen, Carlsbad,
CA, USA); Super Signal West Dura, and EZ-link
sulfo-NHS-LC-LC-biotin (Pierce Chemical Co., Rock-
ford, IL, USA); peptide N-glycosidase F (Prozyme
Inc., San Leandro, CA, USA); polyclonal antirat D1R
antibody (Research Genetics, Huntsville, AL, USA)
[47]; secondary antibodies for immunoblotting studies
(Jackson ImmunoReseach Labs, Inc., West Grove, PA,
USA); secondary antibodies for immunofluorescence
studies (Molecular Probes, Inc., Eugene, OR, USA); im-
munoblotting detection reagents (ECL), and molecular
mass standards (Amersham Corp., Arlington Heights,
IL, USA); 3H-SCH23390 (Perkin Elmer, Boston, MA,
USA); fenoldopam, SCH23390, and other chemicals,
including MES (2-N-morpholino ethanesulfonic acid),
n-octyl-b-D-glucopyranoside, and (+)-butaclamol
(Sigma-Aldrich Chemical Co., St. Louis, MO, USA);
cell culture reagents (Life Technologies-Gibco/BRL,
Rockville, MD; and ATCC, Manassas, VA, USA).
Construction of tagged hD1Rs and transfectants
The original full-length human D1 receptor (hD1R)
cDNA [48], modified to contain a myc-His tag at its car-
boxy terminus, using polymerase chain reaction (PCR),
was cloned into pcDNA6 (Invitrogen). The sequence-
confirmed-engineered hD1R cDNA was transfected into
HEK-293 cells using lipofectamine and selected with 5
to 10 lg/mL blasticidin. The stable transfectants, repre-
senting HEK-hD1Rs, had a dissociation constant (Kd)
of 7.95 ± 1.48 nmol/L, and a receptor density (Bmax) of
3.07 ± 1.13 pmol/mg plasma membrane protein (N = 4),
determined by radioligand binding, using 3H-SCH23390
and 10 lmol/L (+)-butaclamol to define nonspecific bind-
ing. The D1R-expressing cells were further identified by
fluorescence staining with anti-His and anti-myc mon-
oclonal antibodies and laser confocal microscopy (data
not shown). The empty vector-transfected cells served as
negative controls (data not shown). The HEK-hD1R cells
responded appropriately to the D1R agonist, fenoldopam
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(10 lmol/20 minutes), which markedly increased cAMP
accumulation (≈ ninefold over baseline values) (see
Fig. 7B).
Cell culture and cell fractionation
The stable transfectants, HEK-hD1R cells, were main-
tained at 37◦C in a humidified atmosphere with 5%
CO2 in complete medium [MEM with 10% fetal bovine
serum (FBS) and 5 lg/mL blasticidin]. Immortalized rat
RPTCs were maintained in Dulbecco’s modified Ea-
gle’s medium (DMEM)/F12 complete medium [47, 49].
The cells were grown to 90% confluence in 150 mm
dishes. Caveolae and lipid rafts were obtained by su-
crose gradient centrifugation using a detergent-free pro-
tocol according to Song et al [15]. Briefly, the cells were
prestarved in serum-free MEM (SFM) for 2 hours, and
then treated with vehicle (control), or the D1R agonist,
fenoldopam (10 lmol/L), for 10 minutes. The cells were
then rinsed, pelleted into 1.5 mL of 500 mmol/L sodium
carbonate, pH 11, and homogenized with a Dounce ho-
mogenizer (10 strokes), a Polytron tissue grinder (three
10-second bursts), and a sonicator equipped with a con-
ical tip (three 30-second bursts). The homogenate was
diluted 1:2 with 80% sucrose, overlaid with 6 mL 35% su-
crose and 3 mL 5% sucrose, and centrifuged at 160,000g
in a Beckman SW41 rotor at 4◦C for 18 hours. All su-
crose solutions were prepared in MES-buffered saline
(MBS) [(mmol/L) 25 MES, pH 6.7, 150 NaCl, 5 ethylene-
diaminetetraacetic acid (EDTA), 1 phenylmethylsul-
fonyl fluoride (PMSF), 5 dithiothreitol (DTT), leupeptin
(10 lg/mL), aprotinin (10 lg/mL), and pepstatin A (1
lg/mL)]. The same amount of protein was loaded into
each pair of ultraclear centrifuge tubes (vehicle- and
fenoldopam-treated cells). After centrifugation, 12 1 mL
fractions were collected, and aliquots of each fraction
were mixed with Laemmli buffer, boiled, and subjected
to immunoblotting [49]. All experiments were carried out
at 4◦C in the presence of protease inhibitors, as described
above. Protein concentrations were determined using a
Bio-Rad kit (Bio-Rad, Hercules, CA, USA).
Immunoprecipitation and immunoblotting
For immunoblotting, HEK-hD1R cells were lysed in
MBST buffer (MBS containing 1% Triton X-100), and
centrifuged at 16,000g for 20 minutes. The supernatant
was taken to represent the Triton-soluble fraction. The
pellet was resuspended in 2% sodium dodecyl sulfate
(SDS) by sonication, and the supernatant after cen-
trifugation at 16,000g for 20 minutes was taken to rep-
resent the Triton-insoluble fraction. The samples were
then immunoblotted according to a previously published
protocol [49]. To determine any interaction among
caveolin-1, caveolin-2, and hD1Rs, immunoprecipitation
and immunoblotting were performed as described pre-
viously [47, 49]. Protein from HEK-hD1R cells preincu-
bated for 2 hours in SFM prior to treatment (10 min-
utes) with vehicle (control), a D1R agonist, fenoldopam
(10 lmol/L), a D1R antagonist, SCH23990 (5 lmol/L),
alone or in combination, were extracted with MOG
(MBS containing n-octyl-b-D-glucopyranoside) buffer.
Cell lysates (300 lg protein) were mixed with specific
monoclonal anti-His (2 lg) or anti-myc antibodies (1 lg)
and incubated at 4◦C overnight. The next day, protein G
beads (50 lL) were added to each sample with rocking
for 2 hours. The immunocomplexes were washed three
times with phosphate-buffered saline (PBS), the bound
protein eluted by the addition of 40 lL of Laemmli buffer,
and boiled for 8 minutes. The samples were subjected to
SDS-polyacryalmide gel electrophoresis (PAGE) (4% to
20% gradient gel) and immunoblotted with the specific
monoclonal anticaveolin-2 antibody.
To determine the interaction between caveolin-2 and
endogenously expressed D1Rs, immortalized rat RPTCs
were used in some experiments. Cell lysates (500 lg)
were immunoprecipitated with polyclonal anti-D1R an-
tibody and the immunocomplexes were subjected to
immunoblotting with monoclonal anticaveolin-2 anti-
body. The immunoblotting and quantification of the im-
munoblots were performed, as described previously [47,
49].
Biotinylation of cell surface membrane of hD1Rs
in HEK-hD1 cells
Biotinylation of the cells was performed according
to the manufacturer’s instructions. In brief, cells were
grown in 6-well plates to 90% confluence in complete
medium. Cells were washed twice with cold SFM and
then incubated with the cell impermeant biotinylation
reagent, EZ-link sulfo-NHS-LC-LC-biotin (500 lg/mL
in SFM on ice for 20 minutes). Cells were washed three
times with cold PBS containing (mmol/L) 10 glycine,
pH 7.0, 0.1 CaCl2, and 1 MgCl2 to stop the reac-
tion and remove the excess biotin reagent. Cell lysates
(MOG buffer) were subjected to immunoprecipitation
with either anti-myc or anti-His antibodies, and then
immunoblotted with horseradish peroxidase-conjugated
streptavidin. The biotinylated protein bands were visual-
ized by ECL reagents.
Immunofluorescence and confocal microscopy
Dual immunofluorescence staining was performed, as
described [50]. HEK-hD1R and RPTCs, grown on glass
coverslips, were preincubated for 2 hours in SFM. The
cells were then treated with vehicle or drugs at the indi-
cated time. Cells were washed once with cold PBS and
fixed with cold 100% methanol at −20◦C for 20 minutes.
Caveolin-2 was detected using rabbit anticaveolin-2 fol-
lowed by Alexa-568 antirabbit antibody and anti-D1R
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detected by monoclonal anti-His tag antibody followed
by Alexa-488 antimouse antibody in hD1R expressing
HEK-293 cells. The fluorescence images were acquired
using an Olympus Fluoview FV600 laser scanning con-
focal microscope equipped with an 60×/1.4 N.A. objec-
tive. Images were obtained at excitation wavelengths of
488 nm or 543 nm; emission was detected at 535 nm or
645 nm. Single wavelength excitation images were ac-
quired for the green and red fluorescence images to avoid
bleed through of the green into the red channels. Image
acquisition parameters were identical for anticaveolin-
2 detection comparing control and fenoldopam treat-
ment. Similarly, imaging was the same for D1R detec-
tion. Non-saturated images were subjected to quanti-
tative colocalization image analysis using Metamporph
version 6.1 colocalization module (Universal Imaging,
Downington, PA, USA). Images were thresholded to
exclude noncellular-associated area on the coverslip and
to exclude nuclear volumes. The areas stained by anti-
D1R or anticaveolin-2 were determined and compared
for control and fenoldopam conditions and were not sig-
nificantly different using the Student t test. Colocaliza-
tion was defined as pixels (area) of D1R that was coin-
cident with pixels also positive for caveolin-2, expressed
as % of D1R positive pixels. Five independent experi-
ments (immunofluorescence experiments) were carried
out and data from 15 images (control) and 18 images
(fenoldopam) were pooled.
Adenylyl cyclase activity
Because the sucrose gradient fractions 1 and 2 had min-
imal protein and did not express hD1Rs, studies were per-
formed in membranes from sucrose gradient fractions 3
to 12. The membranes (0.3 mL/fraction) were diluted to
3 mL with (mmol/L) 10 Tris-HCl, pH 7.4, 1 MgCl2, and 0.8
EGTA (TME) buffer containing protease inhibitors and
subjected to ultracentrifugation at 100,000g for 30 min-
utes. The pellet from each fraction was re-suspended in
0.3 mL of TME buffer by sonication. Adenylyl cyclase ac-
tivity (40 lL membrane/fraction) was measured accord-
ing to published protocol [51]. Each assay mixture, con-
taining 40 lL membrane in a total volume of 100 lL of
assay buffer [(mmol/L) 30 Tris-HCl, pH 7.2, 0.8 EGTA, 5
MgCl2, 0.1 ATP and 0.05 GTP, 0.05 1 3-isobutyl-1-methyl
xanthine (IBMX), 20 phosphocreatine, and 10 U/assay
of creatine phosphokinase], was incubated at 37◦C for
10 minutes with or without fenoldopam. The reaction was
stopped by heating the samples at 80◦C for 10 seconds and
adding ZnSO4. The samples were acetylated prior to the
radioimmunoassay of cAMP in duplicate.
Caveolin-2 oligonucleotides and cAMP accumulation
Phosphorothioate-substituted antisense (5′-GTCCA
CGAAGAGCTGCACGCCCGC-3′) and inverse an-
tisense (5′-CGCCCGCACGTCGAGAAGCACCTG-
3′) oligonucleotides to human caveolin-2 cDNA
(nucleotides 203-226, GenBank accession number
NM001233 [10]) were synthesized (Gene Tools LLC,
Corvallis, OR, USA). For immunoblotting, HEK-hD1R
cells were seeded in 6-well plates (Falcon) (Fisher
Scientific, Pittsburgh, PA, USA), treated with caveolin-2
antisense or inverse antisense (200 nmol/L) oligonu-
cleotides and lipofectin (3 lL/well) in SFM for 5 hours,
and cultured in complete medium for a total of 48 hours.
Cells were harvested and lysed in MOG buffer. For
cAMP assay, the cells were seeded in 12-well plates
(Falcon), incubated with caveolin-2 antisense or inverse
antisense oligonucleotides, as above for 48 hours, and
then treated with fenoldopam (10 lmol/L), or vehicle
for 20 minutes at 37◦C in MEM, containing (mmol/L)
10 Hepes, pH 7.4, 0.1 ascorbic acid, and 1 3-IBMX.
The cells were lysed in 0.1 N HCl and stored at −70◦C
until assayed for cAMP [51]. All cAMP assays were
performed in triplicate.
Data are expressed as mean ± standard error. Signifi-
cance between groups was determined by Student t test.
Significance among groups was determined by analysis of
variance (ANOVA) followed by Newman-Keuls test. A
P value <0.05 was considered significant.
RESULTS
hD1R expression
Immunoreactive hD1Rs were detected in Triton-
soluble and -insoluble preparations (Fig. 1A). The major-
ity of the hD1Rs were expressed in the Triton-insoluble
fraction with molecular sizes ranging from 75 to 250 kD;
a major 50 kD band and a minor 75 kD band were seen
in the Triton-soluble fraction. A 33 kD band was seen in
the Triton-insoluble fraction and cell lysates of the empty
vector-transfected cells. A faint 50 kD band was also seen
in the empty vector-transfected cells. It is noteworthy that
only the 75 to 80 kD of hD1R was biotinylated (Fig. 1B)
and glycosylated (Fig. 1C). Treatment of the hD1R with
peptide N-glycosidase F (PNGase-F), an endoglycosidase
enzyme, decreased the amount of 75 kD protein band and
resulted in the appearance of a 45 kD band. The results
indicate that the 75 kD species of hD1R is an N-linked
glycosylated protein and is located on the cell surface
membrane.
Membrane localization of hD1Rs
To determine the membrane microdomain localization
of hD1Rs, subcellular cell fractions were obtained using
the detergent-free method reported by Song et al [15].
This method allowed the extraction of proteins firmly at-
tached to membranes without solubilizing caveolin. Us-
ing this procedure, that separates caveolae and lipid rafts
Yu et al: Caveolin-2 regulation of the D1 receptor 2171
250
160
75
50
35
30
EV I S
A
250
75
50
B
m
Ig
G
hD
1
250
160
75
50
35
30 1 2 3 4
PNGase − − + +
C
Fig. 1. Expression of human dopamine re-
ceptors (hD1Rs). (A) hD1Rs stably expressed
in human embryonic kidney (HEK)-293 cells.
Proteins (20 lg) from the Triton soluble (S)
and insoluble (I) fractions from HEK-hD1R
cells were immunoblotted with anti-myc an-
tibody. The high molecular size (75 to 250
kD) hD1Rs were localized in Triton-I fraction
while the 50 and 75 kD hD1Rs were mainly in
Triton-S fraction; a minor 33 kD band was also
noted in the Triton-I fraction. HEK-293 cells
stably transfected with the empty vector (EV)
(negative control) also expressed a 33 kD pro-
tein in the total cell lysate. A 50 kD band was
also noted in EV cells but to a lesser degree
than with the hD1R transfectants. The blot
shown is one of three separate experiments.
(B) Biotinylation of hD1Rs. HEK-hD1R cells
were washed with cold phosphate-buffered
saline (PBS) buffer and incubated with a cell
membrane impermeant biotin reagent (EZ-
link sulfo-NHS-LC-LC-biotin). The cell lysate
proteins were immunoprecipitated and im-
munoblotted as described in the Methods sec-
tion. A broad 75 kD hD1R band was biotiny-
lated and immunoprecipitated with anti-his
antibody under basal conditions. Similar re-
sults were obtained using anti-myc (data not
shown). mIgG is mouse IgG. The blot shown
is one of three separate experiments. (C)
Deglycosylation of hD1Rs. HEK-hD1R cells
were lysed in sodium dodecyl sulfate (SDS)
buffer with 2-mercaptoethanol and boiled for
5 minutes. The proteins (20 to 40 lg) were
treated with (+) or without (−) peptide N-
glycosidase F (PNGase F) (60 U/mL) in reac-
tion buffer overnight at 37◦C and subjected to
immunoblotting with anti-myc antibody. The
broad band of 75 kD hD1R decreased and a 45
kD band appeared following PNGase F treat-
ment. Protein amounts were 20 lg in lanes
1 and 3 and 40 lg in lanes 2 and 4. The blot
shown is one of two separate experiments per-
formed in duplicate.
from the bulk of cellular membranes and cytosolic pro-
teins, we found that caveolin proteins were best recovered
in the low sucrose density fractions, as has been reported
by others [15, 18, 30]. The protein fractions from HEK-
hD1R cells were probed with monoclonal anti-His or myc
antibodies. The high molecular mass (75 to 80, 160 to
250 kD) hD1Rs were localized mainly in the low density
membrane fractions (LDMF) (fractions 3 to 5) (Fig. 2A).
The lowest molecular mass (50 kD) hD1Rs were found in
the high density membrane fractions (HDMF) (fractions
9 to 12). Fenoldopam treatment increased the quantity
of the 50 and 75 kD hD1Rs, did not affect the amount of
the 160 kD hD1Rs, and decreased the amount of 250 kD
D1R protein in both the LDMF and HDMF (Fig. 2A).
Although we did not determine the cause of the increase
in the 50 and 75 kD hD1Rs following agonist treatment,
we suggest that it may have been caused by translocation
from other fractions or from the 250 kD D1R in both
LDMF and HDMF. It has been reported that A1 adeno-
sine receptors convert from a 74 kD species to 36 kD
species following agonist stimulation [24]. Regardless of
the source of the lower molecular species of hD1Rs, our
data showed expression of hD1Rs in two pools, one con-
taining the low molecular mass hD1Rs (50 kD) in non-
raft plasma membranes, and the other containing the high
molecular mass hD1Rs located in lipid rafts that also con-
tain flotillin-1 and caveolin-2 (Fig. 3). D1R agonist stimu-
lation with fenoldopam also induced a shift of the 75 kD
hD1R from fraction 4 to 3 (Fig. 2A).
Sucrose gradient analysis of adenylyl cyclase activity
We next determined the hD1R-stimulated adenylyl cy-
clase activity in various fractions of the sucrose density
gradient in order to gain insight into the second messen-
ger coupling efficiency associated with each membrane
fraction (Table 1). As shown in Figure 2B, protein concen-
trations were greater in HDMFs (90%), than in LDMFs
(7.6%) (right ordinate). Because protein concentrations
in fractions 1 and 2 were negligible, we measured adeny-
lyl cyclase activity only from sucrose gradient fractions
3 to 12. Fenoldopam increased adenylyl cyclase activity
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Fig. 2. Sucrose density gradient analysis of human dopamine recep-
tors (hD1Rs). (A) hD1Rs in sucrose density gradient fractions human
embryonic kidney (HEK)-hD1R cells, treated with vehicle (control) or
the D1R agonist, fenoldopam (10 lmol/L, 10 minutes), were subjected
to sucrose gradient centrifugation as described in the Methods section.
Twelve fractions (numbered from top to bottom, fractions 1 to 12) were
subjected to immunoblotting (25 lL/fraction/lane) with specific mon-
oclonal anti-His antibodies. At basal conditions (control), hD1Rs had
two broad bands with molecular sizes of 75 and 160 to 250 kD in the
low density membrane fraction (LDMF) (fractions 4 and 5); minimal
staining was seen in fraction 12. A 50 kD band was seen mainly in the
high density membrane fractions (HDMFs) (fractions 9 to 12). In the
LDMFs (fractions 3 to 5), the D1R agonist, fenoldopam (10 lmol/L,
10 minutes), decreased the 250 kD band and increased both the 50 and
75 kD bands; the 75 kD band was shifted to an even lower density
fraction (from fraction 4 to 3) with agonist treatment. In the HDMFs,
fenoldopam minimally increased the 50 kD hD1R and minimally de-
creased the 250 kD species. The blots shown are from one of three sep-
arate experiments. MS is molecular size. (B) Adenylyl cyclase activity
in sucrose gradient fractions. Membranes were obtained from each su-
crose gradient fraction and adenylyl cyclase activity (left ordinate) was
measured with and without the D1R agonist, fenoldopam, as described
in the Methods section. The protein concentrations (right ordinate) of
each of the 12 fractions were also measured using bovine serum albumin
(BSA) as a standard. Fenoldopam increased adenylyl cyclase activity
to a greater extent in LDMFs, especially in fraction 4 (192%), than in
HDMFs (fractions 9 to 12). More than 90% of the cellular proteins were
in HDMFs (fractions 9 to 12), while less than 10% of the cellular pro-
teins were in LDMFs (fractions 3 to 6). The results are mean ± SE from
three separate experiments. ∗P < 0.05, analysis of variance (ANOVA)
and Newman-Keuls test.
(left ordinate) (Table 1) to a greater extent in LDMFs
than HDMFs. The fenoldopam-mediated increase in to-
tal adenylyl cyclase activity was 219.6 ± 28.6 in fractions
3 to 6 and 9.2 ± 1.3 pmol/mg plasma membrane pro-
tein/min (N = 3) in fractions 9 to 12. Thus, fenoldopam in-
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Fig. 3. Sucrose density gradient analysis of caveolin-2 and flotillin pro-
teins. Human embryonic kidney-human dopamine receptor (HEK-
hD1R) cells, treated with vehicle (control) or the D1R agonist,
fenoldopam (FEN) (10 lmol/L, 10 minutes), the D1R antagonist,
SCH23390 (5 lmol/L), or in combination (SCH + FEN), were sub-
jected to sucrose gradient centrifugation, as described in the Methods
section. Proteins in the sucrose density gradient fractions were probed
with monoclonal anticaveolin-2 antibody. Caveolin-2 isoforms (Cav-2)
were concentrated in low density membrane fractions (LDMFs) (frac-
tions 3 to 5) with minimal expression in high density membrane fractions
(HDMFs) (fractions 9 to 12). Caveolin-2a was more abundant than
caveolin-2b and -2c. The fractions were also blotted with anticaveolin-
1 and caveolin-3 antibodies. Neither caveolin-1 (22 kD) nor caveolin-3
protein was detected even with the use of “Super Signal” (data not
shown). The same proteins were probed with monoclonal antiflotillin-1
antibody. Flotillin-1 (Flo-1) expression was similar to the pattern noted
with caveolin-2 and was slightly but not significantly greater in LDMFs
(fractions 1 to 6) (53.5 ± 3.1%) than in HDMFs (fractions 7 to 12) (46.5
± 3.1%). Flo-1 was also expressed in HDMFs which contain proteins
in cytosol, trans-Golgi network, and nonrafts plasma membranes. The
blots are representative of three separate experiments.
creased adenylyl cyclase activity 20-fold higher in LDMFs
than in HDMFs. Comparing each fraction individually,
fenoldopam produced the greatest increase in adenylyl
cyclase activity in fraction 4 (% change of control, left
ordinate) (Fig. 2B).
Sucrose gradient analysis of caveolin-2 and flotillin-1
We next determined whether caveolins (especially
caveolin-1), a caveola marker protein [3, 4], and flotillin-
1, a lipid raft marker protein [52–55], were expressed
in the HEK-293 cells. Endogenous caveolin-1 is mini-
mally expressed in some but not in all clones of HEK-293
cells [56]. Caveolin antibodies, obtained from the same
source as a previous report [56] did not detect caveolin-1
or caveolin-3 even with “super signal” blotting method
(data not shown) in our HEK-293 cells. To increase the
chance of detecting caveolin-1 in our HEK-293 cells,
caveolin-1 was immunoprecipitated with caveolin-1 anti-
bodies prior to immunoblotting. However, the band ob-
tained (18 kD) was less than the expected size (22 kD),
compared with a commercially available positive con-
trol (data not shown). In contrast, the molecular sizes
Yu et al: Caveolin-2 regulation of the D1 receptor 2173
Table 1. Adenylyl cyclase activity in membranes from the sucrose gradient fractions in human embryonic kidney-human D1 (HEK-hD1) cells
Adenylyl cyclase activity pmol/mg protein/min
Fractions 3 4 5 6 7 8 9 10 11 12
Control 47.9 ± 11.7 42.5 ± 20.8 36.1 ± 13.3 33.3 ± 7.7 23.1 ± 0.6 22.6 ± 3.4 9.5 ± 1.5 2.0 ± 0.41 1.5 ± 0.1 1.2 ± 0.15
Fenoldopam 85.7 ± 13.8 147 ± 26.9a 114 ± 33.5a 49.8 ± 12.4 26.5 ± 3.9 22.5 ± 2.6 17.3 ± 5.0a 2.9 ± 0.3 1.57 ± 0.2 1.6 ± 0.1
aP < 0.050 vs. corresponding control, analysis of variance (ANOVA), and Newman-Keuls test.
of the caveolin-2 bands were appropriate for the cloned
isoforms. The majority of the endogenously expressed
caveolin-2 and its three isoforms (a, b , and c) [57] in
HEK-293 cells were detected (by immunoblotting) in
the Triton-insoluble fraction with an expression pattern
of caveolin-2a > caveolin-2b > caveolin-2c. Caveolin-
2a, but not caveolin-2b and 2c, was also detected in the
Triton-soluble fraction (data not shown). As shown in
Figure 3, the majority of caveolin-2a and caveolin-2b
were found in the LDMFs (fractions 3 to 5) that cor-
respond to the Triton-insoluble membranes. Caveolin-2
was also found in the HDMFs thought to be associated
with the proteins of the cytosol, trans-Golgi network, and
nonraft membrane proteins [58]. Fenoldopam treatment
increased caveolin-2 expression and shifted the band to
an even lower density fraction, from fraction 4 to fraction
3, similar to that noted with hD1Rs.
Flotillin-1 (48 kD) was expressed in both Triton-soluble
and insoluble fractions (data not shown). Figure 3 shows
that flotillin-1 cofractionated with caveolin-2 in LDMFs.
The subcellular localization of flotillin-2 was similar to
flotillin-1 (data not shown). Flotillin-1 and -2 were en-
riched in the LDMFs, indicating that these two proteins
associate with lipid raft plasma membrane microdomains
that also contain caveolin-2. Like caveolin-2, flotillin-1
also shifted to a lower density fraction by fenoldopam
(Fig. 3). The effect of fenoldopam on both caveolin-2 and
flotillin -1 was blocked by the D1 antagonist, SCH23390,
which by itself had no effect (Fig. 3). It is possible that
caveolin-2, via caveolin-2b , is targeted to the surface of
lipid droplets and serves as a membrane domain [59].
Flotillin-1, via its prohibitin-like domain (PHB) that is
associated with raft domains [53], is involved in lipid raft
shaping and protein trafficking [52, 53].
Caveolin-2 and flotillin cofractionation with signaling
molecules
We next determined whether caveolin-2 cofractionated
with signaling molecules by immunoblotting the sucrose
gradient fractions with anti-GaS, anti-Gb common, anti-
PKAc, anti-PKARIIb , anti-PP2A-B56a, and anti-GRK2
antibodies. As shown in Figure 4, the G protein sub-
units, GaS and Gbc, cofractionated with caveolin-2 in
LDMF (fractions 3 to 5). All the signaling molecules
tested were distributed in two pools (see below), with
the majority in nonlipid rafts and a small amount in
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Fenoldopam
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Fenoldopam
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Gβγ
PKARΠβ
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B56α
GRK2
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Fig. 4. Caveolin-2 cofractionation with human dopamine receptor
(hD1R) signaling molecules. The proteins from the sucrose gradient
fractions used in Figure 2A were subjected to immunoblotting with
the specific antibodies described in the Methods section. G protein
subunits, GaS, Gbc, protein kinase A (PKA) regulatory subunit II
(PKARIIb ), PKA catalytic (PKAc), protein phosphatase regulatory
subunit (PP2A-B56a), and G protein receptor kinase 2 (GRK2) cofrac-
tionated with caveolin-2. Fenoldopam shifted the expression of the sig-
naling molecules to an even lower density fraction similar to that noted
with hD1R (Figure 2A) and caveolin-2 (Figure 3). The blots are from
one of three separate experiments.
lipid raft fractions. The cofractionation of Gbc, a preny-
lated protein, with caveolin-2, suggest that prenylated
proteins were retained with the carbonate-based pro-
tein extraction method, in agreement with a previous
report [15]. The proteins involved in the downstream sig-
naling cascade following stimulation of adenylyl cyclase,
PKAc and PKARIIb , also cofractionated with caveolin-2.
In addition, proteins that are involved in the desensitiza-
tion (GRK2) [37, 38] and resensitization (protein phos-
phatase 2A regulatory subunit, PP2A-B56a) of the D1R
[49] also cofractionated with caveolin-2. Interestingly, the
major GRK, GRK4, involved in the desensitization of
the D1R, in renal proximal tubules [39, 40] was not found
in lipid rafts. The major sodium transporter in the lu-
minal membrane of renal proximal tubules, sodium hy-
drogen exchanger 3 (NHE3) was found only in HDMFs,
and also did not cofractionate with caveolin-2 (data not
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Fig. 5. Effect of a dopamine receptor (D1R) agonist on the association
of caveolin-2 with human D1Rs (hD1Rs). (A) Time course of the
effect of a D1R agonist, fenoldopam, on the association of caveolin-2b
with hD1Rs. Human embryonic kidney (HEK)-hD1R cells, starved in
serum-free medium (SFM) prior to incubating the cells in vehicle or
fenoldopam (10 lmol/L) for the indicated times at 37◦C, were lysed
and subjected to immunoprecipitation (anti-myc antibody) and im-
munoblotting as described in the Methods section. hD1R/caveolin-2b
immunoprecipitates increased at 5 minutes [29.1 ± 4.8 density units
shown). Sodium potassium ATPase, a basolateral mem-
brane marker, was mainly found in the LDMFs in HEK-
293, similar to a previous report [60].
Stimulation of D1Rs, as with other GPCRs, induces the
dissociation of their heterotrimeric G proteins into a and
bc subunits; GaS and Gbc subunits regulate distal events,
including stimulation of adenylyl cyclase, which leads to
the production of cAMP and activation of PKA [61–63].
The PKA holoenzyme is a heterotetramer containing two
catalytic subunits bound to a homodimer of two regula-
tory subunits RI (RIa, RIb) and RII (RIIa and RIIb)
[64]. PKARIIb , the RII that is predominantly expressed
in the rat and human kidney cells, has been suggested as
the PKA isoform regulating D1R function [61, 62]. It has
been reported that cAMP-associated signaling molecules,
such as adenylyl cyclase and PKA, are localized in caveo-
lae, and are regulated by caveolae proteins (i.e., the cave-
olins) [16]. The D1R agonist, fenoldopam, shifted these
signaling molecules, including PKARIIb , to an even lower
density fraction, similar to the pattern noted with hD1Rs,
caveolin, and flotillins-1 and -2.
D1R agonist-promoted association of caveolin-2b
with hD1R
To evaluate agonist regulation of hD1R associa-
tion with caveolin-2 and the role of caveolin-2 in the
D1R signaling, coimmunoprecipitation studies were per-
formed. Fenoldopam transiently increased the amount
of hD1R/caveolin-2b (threefold), peaked at 5 to 10 min-
utes, and returned to baseline at 30 minutes (Fig. 5A).
There was no association of hD1R with caveolin-2a or
caveolin-2c. We also did not observe any association of
the hD1R with caveolin-1 protein even with the use of
“super signal” substrate kit (data not shown).
(DU)] and 10 minutes (31.2 ± 4.4 DU) and returned to base line at
30 minutes (9.3 ± 2.3 DU). ∗P < 0.05 versus others (N = 5), analysis
of variance (ANOVA), and Newman-Keuls test, following fenoldopam
treatment. The inset is one of five immunoblots. Abbreviations are:
PC, positive control; mIgG, mouse IgG. (B) HEK-hD1R cells were
treated with vehicle (control), the D1R agonist fenoldopam (FEN)
(10 lmol/L), the D1R antagonist, SCH23990 (SCH) (5 lmol/L), alone
or in combination (FEN + SCH) for 10 minutes at 37◦C. Cell lysates
were subjected to immunoprecipitation (anti-myc antibody) and im-
munoblotting. Fenoldopam increased the amount of caveolin-2b that
coimmunoprecipitated with hD1Rs. SCH23990, by itself, had no effect,
but did block the stimulatory effect of fenoldopam. ∗P < 0.05 versus oth-
ers (N = 4), ANOVA, and Newman-Keuls test. The inset is one of four
immunoblots. (C) Rat renal proximal tubule cells (RPTCs) were treated
the same as those shown in (B). Cell lysates were immunoprecipitated
with affinity-purified polyclonal anti-D1R antibody (2 lg/sample) and
immunoblotted with anticaveolin-2 antibody [same antibody was used
in (B)]. Fenoldopam increased the amount of caveolin-2a and caveolin-
2b that coimmunoprecipitated with D1Rs. SCH23990, by itself, had no
effect on caveolin-2b/D1R (but slightly increased caveolin-2b /D1R),
but did block the stimulatory effect of fenoldopam. ∗P < 0.05 versus
others (N = 4), ANOVA, and Newman Keuls test. The inset is one of
four to five immunoblots.
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To determine further the specificity of the fenoldopam-
stimulated increase of the association of hD1R with
caveolin-2b , lysates of cells treated with a D1R ago-
nist and/or a D1R antagonist were subjected to coim-
munoprecipitation with anti-myc monoclonal antibodies.
As shown in Figure 5B, fenoldopam (10 lmol/10 min-
utes) increased the amount (2.7-fold) of caveolin-2b that
coimmunoprecipitated with the myc-tagged hD1R. The
D1-like antagonist, SCH23390, by itself, had no effect
on the hD1R/caveolin-2b coimmunoprecipitation, but it
completely prevented the effect of fenoldopam. These
results indicate that fenoldopam specifically promoted
the formation of protein complexes that contained both
caveolin-2b and hD1R, and that the association was me-
diated specifically through the hD1R located in lipid rafts.
The observations indicate that caveolin-2b represents a
novel hD1R-interacting protein.
Although the Kd and Bmax of the hD1Rs heterolo-
gously expressed in HEK-293 cells were similar to D1Rs
endogenously expressed in rat striatum and proximal
tubules [65], we also studied the relationship between en-
dogenously expressed D1Rs and caveolin-2. We used im-
mortalized rat RPTCs because these cells endogenously
express D1Rs [47, 49, 63, 65] and caveolin-2a and 2b but
not caveolin-1 [46]. Fenoldopam increased the amount
of caveolin-2a (twofold) and 2b (threefold) association
with D1Rs (Fig. 5C). The results indicate that caveolin-2a
and 2b can form a protein complex with endogenously
expressed D1Rs and offer additional proof that a com-
plex can occur in the absence of caveolin-1, similar to
that described for gonadotrophin releasing hormone re-
ceptor [30]. It should be noted that the stimulatory effect
of fenoldopam on D1R/caveolin-2b coimmunoprecipita-
tion was completely prevented by the D1R antagonist,
SCH23990, which by itself had no effect. In contrast,
SCH23390, by itself had a slight stimulatory effect on
D1R/caveolin-2a coimmunoprecipitation.
The interaction between caveolin-2 and D1Rs detected
by coimmunoprecipation was corroborated by laser con-
focal microscopy (Fig. 6). In vehicle-treated cells, hD1Rs
were localized mainly at the plasma membrane. Caveolin-
2 staining was seen near the plasma membrane, and
in the cytosol. Colocalization of D1R with caveolin-
2 was quantified for control and fenoldopam-treated
cells and expressed as % of total D1R area colocalizing
with caveolin-2 (see the Methods section). Colocaliza-
tion of D1R increased approximately 1.4-fold following
fenoldopam treatment, from 54 ± 4% (control) to 78 ±
3% (fenoldopam) (Fig. 6A). Even through confocal mi-
croscopy is limited in resolution to about 0.5 lm in the z di-
mension, these data clearly showed a significant shift (P =
0.0004, N = 15 to 18) toward increased colocalization fol-
lowing fenoldopam treatment and are consistent with the
finding that caveolin-2 coimmunoprecipitates with D1R.
We could not determine the isoform of caveolin-2 that
colocalized with hD1Rs, because the anticaveolin-2 mon-
oclonal antibody used recognized all three isoforms of
caveolin-2 [57]. The colocalization of D1R and caveolin-2
that became apparent with fenoldopam stimulation de-
tected by confocal microscopy was also observed in rat
RPTCs (Fig. 6B).
Effect of antisense caveolin-2 oligonucleotides on cAMP
accumulation
To explore further the role of caveolin-2 in D1R sig-
naling, hD1R-mediated cAMP accumulation was studied
following the suppression of caveolin-2 protein expres-
sion. Caveolin-2 expression was suppressed by caveolin-
2 antisense oligonucleotides (60%), while inverse
antisense oligonucleotides had no effect (Fig. 7A). An-
tisense caveolin-2 oligonucleotides also decreased the
stimulatory effect of the D1R agonist, fenoldopam, on
cAMP accumulation by 30% (Fig. 7B). The modest de-
crease in fenoldopam-stimulated cAMP accumulation
relative to the marked inhibition of caveolin-2 expres-
sion with antisense treatment is of interest. Endoge-
nous expression of caveolin-2, specifically caveolin-2b
when compared with caveolin-2a (Figs. 3, 5A and B), is
limited in HEK-293 cells. This may indicate that caveolin-
2-regulated D1R action is but one of several other regula-
tors of the D1R. The magnitude of the increase in cAMP
concentration is much greater in whole cells (Fig. 7B)
than in the membrane fractions shown in Figure 2B. It
is possible that a higher level of caveolin-2b expression
may be needed to regulate the hD1R in the membranes
that are now devoid of cytoplasmic cofactors. One to
one comparison may not be possible, however, because
adenylyl cyclase activity (in membranes) was measured
in the studies shown in Figure 2B while cAMP accu-
mulation was measured in whole cells (Fig. 7B). More-
over, D1 receptors are located not only in the surface
membranes but also intracellularly. D1 receptor stimu-
lation recruits intracellular receptors to the membrane
surface, increasing the D1 receptor response which is no
longer possible when membrane fractions are used. In
spite of these caveats, the inhibitory effect of antisense
caveolin-2 oligonucleotides on D1R-induced cAMP ac-
cumulation suggest that the caveolin-2 was required for
D1R-mediated signal transduction. These results support
the conclusion that caveolin-2 regulated D1R signaling
but the isoform involved could not be determined be-
cause the caveolin-2 antisense oligonucleotides inhibited
all three isoforms of caveolin-2 (data not shown).
DISCUSSION
In the current studies, using a carboxy terminus-tagged
hD1R, we found evidence for the existence of several
molecular species of hD1Rs (50, 75 to 80, 160 to 250 kD).
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Fig. 6. Colocalization of caveolin-2 with human dopamine receptors (hD1Rs) determined by laser confocal microscopy. Human embryonic kidney
(HEK)-hD1R (A) and renal proximal tubule cells (RPTCs) (B) were treated with vehicle (control) or a D1R agonist, fenoldopam (10 lmol/L for
10 minutes) and double immunofluorescence staining was performed with monoclonal anti-myc antibody for hD1R and polyclonal anticaveolin-2
antibody (A), or polyclonal anti-rat D1R antibody and monoclonal anti-caveolin-2 (B). Confocal images showed D1Rs (green) (A) (red) (B) in
plasma membranes and caveolin-2 (red) (A) (green) (B) in plasma membrane and intracellular compartments. Colocalization was seen as a yellow
color in “Merge.” In untreated cells, little or no colocalization was seen. Colocalization of caveolin-2 with hD1Rs in clusters was increased with
fenoldopam treatment. The image is one of at least three to five separate experiments for each panel. Bar = 30 lm (A), 20 lm (B).
Some of the hD1R species were similar to those described
for D1Rs detected by polyclonal and monoclonal anti-
bodies in humans and other animals such as rats, dogs,
and cows [42, 48, 66–69]. Our data provide strong evi-
dence that D1Rs are located in two compartments: the
50 kD D1Rs in nonraft plasma membranes and the 75
to 250 kD D1Rs in lipid rafts. The 75 kD hD1R is able
to undergo biotinylation and deglycosylation, suggesting
that the hD1R is a cell surface membrane glycoprotein,
in agreement with other reports [67, 68]. The increase in
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Fig. 7. Effect of caveolin-2 antisense oligonucleotides on caveolin-2
expression and cyclic adenosine monophosphate (cAMP) accumula-
tion. (A) Effect of caveolin-2 antisense oligonucleotides on caveolin-
2 expression. Human embryonic kidney-human dopamine receptor
(HEK-hD1R) cells treated with vehicle, human caveolin-2 antisense
(AS), or inverse antisense (INV) oligonucleotides for 48 hours, as de-
scribed as in the Methods section, were lysed in MBST buffer and the
samples (20 lg/lane) subjected to immunoblotting with anticaveolin-2
antibody. Caveolin-2 expression was suppressed (60%) by antisense
but not by inverse antisense oligonucleotide treatment. The results
are mean ± SE from five separate experiments. ∗P < 0.01, analysis
of variance (ANOVA), Newman-Keul test. The inset is one of five
immunoblots. DU is density units. (B) Effect of caveolin-2 antisense
oligonucleotides on cAMP accumulation. HEK-hD1R cells, treated
with human caveolin-2 antisense and inverse antisense oligonucleotides
as in (A) were assayed for cAMP as described in the Methods section.
Basal cAMP levels were 23.6 ± 2.0, 23.0 ± 3.3, and 29.5 ± 0.75 pmol/mg
membrane protein/min in vehicle (control), antisense and inverse anti-
sense oligonucleotide-treated cells, respectively. Fenoldopam increased
cAMP accumulation 9.1-fold in nonoligonucleotide-treated cells and
8.8-fold in inverse antisense oligonucleotide-treated cells. Caveolin-2
antisense oligonucleotides decreased the effect of fenoldopam by 30%.
The results are mean ± SE from six separate experiments. ∗P < 0.05,
ANOVA and Neuman-Keuls test.
adenylyl cyclase activity induced by D1R agonist stimu-
lation in both lipid rafts and nonraft membranes further
supports the notion that hD1Rs are distributed in two
compartments. The increase in the quantity of 50 and
75 kD hD1Rs in lipid rafts induced by the D1R agonist is
in agreement with the suggestion that lipid rafts may serve
as platforms for attachment of receptors and proteins in-
volved in signal transduction and intracellular traffick-
ing [1–6]. The ability of fenoldopam to increase adenylyl
cyclase activity in nonraft plasma membranes (Fig. 2B),
albeit to a lesser degree than in lipid rafts, also suggest
that D1R-mediated signaling can take place in nonraft
plasma membranes. Previous studies with hD1Rs tagged
at the amino terminus have suggested that the functional
hD1R is the 45 to 50 kD species [42, 43], based on their
localization on the cell surface, and agonist occupancy
leading to D1R phosphorylation, desensitization, and en-
docytosis [42]. However, we found that the greatest in-
crease in adenylyl cyclase activity following D1R agonist
stimulation occurred in lipid raft membranes where the
biotinylatable and glycosylated D1Rs are located. Thus,
our studies indicate that the major functional hD1R is
the 75 kD species. However, the exact functional signifi-
cance of the different forms of hD1R and the changes in
their quantity and location following agonist stimulation
remains to be determined.
A wide array of signaling and scaffolding proteins, and
several GPCRs have been shown to associate with cave-
olae and lipid rafts [5, 6, 31]. Our data show that the high
molecular mass hD1Rs cofractionate with caveolin-2, and
that a D1R agonist promotes the interaction of hD1R
with caveolin-2b rather than caveolin-1, -3, caveolin-2c
(Fig. 5A and B). There may be species variation in the
interaction of D1R with caveolin-2 isoforms because the
D1R endogenously expressed in rat RPTCs associate not
only with caveolin-2b but also with caveolin-2a, albeit
with less specificity than caveolin-2b (Fig. 5C). Never-
theless, the results in rat RPTCs indicate that the interac-
tion of caveolin 2 with hD1Rs heterologously expressed
in HEK-293 cells cannot be explained by promiscuous
association of overexpressed receptors. It has been noted
earlier that the Kd and Bmax of the hD1R heterologously
expressed in HEK-293 cells are similar to D1Rs endoge-
nously expressed in rat striatum and proximal tubules
[65].
D1R agonist stimulation increases the association of
hD1Rs and caveolin-2b in a time-dependent manner. The
relatively short time frame (10 minutes) in which the phe-
nomenon occurs suggests that the increase in protein ex-
pression may have resulted from their translocation or
recruitment from other compartments. It is possible that
fenoldopam converted the high molecular size D1Rs to
the 75 kD D1R in LDMFs (Fig. 2A), with subsequent re-
cruitment into clustering vesicles containing caveolin-2
(Fig. 6A), resulting in increased association of caveolin-2
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to D1R in LDMFs (Fig. 5A and B). The association of
caveolin-2 with the activated D1R is specific because the
effects of the D1R agonist are blocked by a D1R antag-
onist. The inhibition of D1R-mediated cAMP accumu-
lation by caveolin-2 antisense oligonucleotides further
supports the conclusion that caveolin-2 is an important
regulator of D1R signaling. Interestingly, Fujimoto et al
[59] have shown that caveolin-2b is targeted to the sur-
face of lipid droplets and that lipid droplets in cell sur-
face membranes may serve as membrane microdomains.
This would indicate that caveolin-2, specifically caveolin-
2b tagged to lipid droplets, with flotillins, can, indeed,
function as membrane microdomains in the absence of
caveolin-1. Gonadotrophin releasing hormone receptors
are also located in noncaveolar (without caveolin-1) lipid
rafts [30]. The translocation of GPCR binding activity
(m2 mAchR, A1 adenosine and B2 bradykinin receptors)
into or out of caveolae and rafts may allow the receptor to
interact with G proteins and downstream effectors con-
centrated in these microdomains [20, 22, 24, 25]. The en-
richment of both hD1R and signaling molecules in lipid
rafts could serve to facilitate the efficient signal transduc-
tion of the hD1R.
In our studies, caveolin-2, rather than caveolin-1 or 3,
and flotillin-1 and -2 are expressed in the HEK-239 cell,
an RPTC line. Rat RPTCs also do not express caveolin-
1 or form caveolae [46]. In the absence of caveolin-1,
caveolin-2 could not form caveolae [57, 58]. Flotillin-1
belongs to a new family of integral membrane proteins
that form stable hetero-oligomers and can form caveolae
in the presence of caveolin-1 [55]. However, flotillins have
also been reported to be important components of lipid
rafts in cells that do not express caveolins (e.g., neurons,
glial cells, human erythrocytes) [3, 54]. Our data showing
the cofractionation of hD1Rs with caveolin-2 and flotill-
ins indicate that these proteins coreside in lipid rafts. The
hD1R also co-fractionates with several signal transduc-
tion proteins such as Gas, Gbc, PKAc, PKARIIb , and
PP2A-B56a, in addition to caveolin-2 and flotillins. D1R
agonist stimulation increases the quantity of 50 to 75 kD
hD1R and shifts them along with caveolin-2, flotillin, and
several signaling proteins to an even lower density frac-
tion, the significance of which remains to be determined.
The D1R agonist-mediated shift of hD1Rs to an even
lower density fraction (fraction 4 to 3) could represent
desensitized and internalized receptors with their inter-
active proteins or recycling receptor complex. Indeed, the
D1R agonist fenoldopam, increases adenylyl cyclase ac-
tivity to a greater extent in fraction 4 than in fraction 3
(Fig. 2B).
D1Rs have been shown to be internalized by clathrin-
dependent and independent pathways [38–43]. In our
studies, most of the immunoreactive clathrin is located
in HDMFs and do not cofractionate with caveolin-2
(data not shown). Other investigators have reported that
clathrin is not enriched in lipid rafts [14, 29]. The lipid raft
and nonraft distribution of D1Rs in plasma membranes,
along with the activation of adenylyl cyclase suggest that
D1R-mediated signaling may have different pathways.
We postulate that the 50 kD D1R internalizes to clathrin-
coated vesicles in nonraft membranes while the 75 kD
D1R internalizes in lipid rafts with subsequent recycling
to the plasma membrane. We have reported that the first
20 minutes of the desensitization of D1Rs in human re-
nal proximal tubule cells are GRK-independent and have
suggested that the initial process of D1R desensitization
may be related to caveolin-2 [40]. We also reported that
both GRK2 and 4 (GRK4>GRK2) are involved in the
desensitization of the hD1R [40]. The failure of GRK4
to cofractionate with caveolin-2 (data not shown) may
provide a mechanism for the GRK4-independent desen-
sitization of the D1R [39, 40]. However, GRK2 which
cofractionates with caveolin-2 is also not involved in
the early desensitization of the hD1R in renal proximal
tubules [40]. The current and previous reports suggest
that there may be more than two pathways of hD1R de-
sensitization in renal proximal tubules [41, 43], but the
details of these pathways remain to be determined. Tak-
ing this reservation into account, we have demonstrated,
for the first time, that caveolin-2, especially caveolin-2b ,
regulates D1R-mediated signaling in human kidney cells.
In cells with minimal or no endogenous caveolin-1, as in
HEK-293 and rat RPTCs, lipid rafts that contain caveolin-
2 and flotillins may serve a similar function as caveolae
[31].
CONCLUSION
We have demonstrated a novel association between
caveolin-2b and D1Rs. We also demonstrated the lo-
calization of hD1R in two membrane compartments in
HEK-293 cells. Caveolin-2b may play an important role
in the regulation of the D1R-mediated signaling. How-
ever, the mechanism by which caveolin-2 regulates D1Rs
or other dopamine receptor subtypes remains to be de-
termined.
ACKNOWLEDGMENTS
These experiments were supported in part by grants from the Na-
tional Institutes of Health, HL23081, DK39308, DK52612, HL68686,
and HL74940, and in part by the Lombardi Comprehensive Cancer
Center Microscopy and Imaging Shared Resource, U.S. Public Health
Service Grant 2P30-CA-51008 and 1S10 RR15768-01. Some of the re-
sults were presented at the Annual Meeting of the American Society
for Cell Biology, December 2000, and the FEBS meeting for Signal
Transduction, July 2003, and Annual Meeting for EB, April 2004.
Reprint requests to Peiying Yu, M.D., Georgetown University Medical
Center, Department of Pediatrics, 3800 Reservoir Road, NW, Washington,
D.C. 20007.
E-mail: yup@georgetown.edu
Yu et al: Caveolin-2 regulation of the D1 receptor 2179
REFERENCES
1. SIMONS K, IKONEN E: Functional rafts in cell membranes. Nature
387:569–572, 1997
2. ANDERSON RG, JACOBSON K: A role for lipid shells in targeting pro-
teins to caveolae, rafts, and other lipid domains. Science 296:1821–
1825, 2002
3. GALBIATI F, RAZANI B, LISANTI MP: Emerging themes in lipid rafts
and caveolae. Cell 106:403–411, 2001
4. LISANTI MP, SCHERER PE, TANG Z, SARGIACOMO M: Caveolae, cave-
olin and caveolin-rich membrane domains: A signaling hypothesis.
Trends Cell Biol 4:231–235, 1994
5. SHAUL PW, ANDERSON RG: Role of plasmalemmal caveolae in signal
transduction. Am J Physiol 275:L843–L851, 1998
6. OSTROM RS, POST SR, INSEL PA: Stoichiometry and compartmenta-
tion in G protein-coupled receptor signaling: Implications for ther-
apeutic interventions involving GS. J Pharmacol Exp Ther 294:407–
412, 2000
7. ROTHBERG K, HEUSER JE, DONZELL WC, et al: Caveolin, a protein
component of caveolae membrane coats. Cell 68:673–682, 1992
8. GLENNEY JR: The sequence of human caveolin reveals identity with
VIP21, a component of transport vesicles. FEBS Lett 314:45–48,
1992
9. KURZCHALIA TV, DUPREE P, PARTON RG, et al: VIP21, a 21-kD mem-
brane protein is an integral component of trans-Golgi-network-
derived transport vesicles. J Cell Biol 118:1003–1014, 1992
10. SCHERER PE, OKAMOTO T, CHUN M, et al: Identification, sequence,
and expression of caveolin-2 defines a caveolin gene family. Proc
Natl Acad. Sci USA 93:131–135, 1996
11. WAY M, PARTON RG: M-caveolin, a muscle-specific caveolin-related
protein. FEBS Lett 376:108–112, 1995
12. TANG Z, SCHERER PE, OKAMOTO T, SONG K, et al: Molecular cloning
of caveolin-3, a novel member of the caveolin gene family expressed
predominantly in muscle. J Biol Chem 271:2255–2261, 1996
13. SARGIACOMO M, SUDOL M, TANG Z, LISANTI MP: Signal transducing
molecules and glycosyl-phosphatidylinositol-linked proteins form a
caveolin-rich insoluble complex in MDCK cells. J Cell Biol 122:789–
807, 1993
14. SMART EJ, YING Y, MINEO C, ANDERSON RGW: A detergent-free
method for purifying caveolae membrane from tissue culture cells.
Proc Natl Acad Sci USA 92:10104–10108, 1995
15. SONG K, LI S, OKAMOTO T, QUILLIAM LA, et al: Co-purification and
direct interaction of Ras with caveolin, an integral membrane pro-
tein of caveolae microdomains. Detergent-free purification of cave-
olae microdomains. J Biol Chem 271:9690–9697, 1996
16. RAZANI B, RUBIN CS, LISANTI MP: Regulation of cAMP-mediated
signal transduction via interaction of caveolins with the catalytic
subunit of protein kinase A. J Biol Chem 274:26353–26360, 1999
17. CARMAN CV, LISANTI MP, BENOVIC JL: Regulation of G protein-
coupled receptor kinases by caveolin. J Biol Chem 274:8858–8864,
1999
18. BATHORI G, PAROLINI I, TOMBOLA F, et al: Porin is present in the PM
where it is concentrated in caveolae and caveolae-related domains.
J Biol Chem 274:29607–29612, 1999
19. CHUN M, LIYANAGE UK, LISANTI MP, LODISH HF: Signal transduc-
tion of a G protein-coupled receptor in caveolae: Colocalization of
endothelin and its receptor with caveolin. Proc Natl Acad Sci USA
91:11728–11732, 1994
20. LAMB ME, ZHANG C, SHEA T, et al: Human B1 and B2 bradykinin
receptors and their agonists target caveolae—related lipid rafts to
different degrees in HEK293 cells. Biochemistry 41:14340–14347,
2002
21. DE WEERD WF, LEEB-LUNDBERG LM: Bradykinin sequesters B2
bradykinin receptors and the receptor-coupled Ga subunits Gaq
and Ga i in caveolae in DDT1 MF-2 smooth muscle cells. J Cell Biol
272:17858–17866, 1997
22. HAASEMANN M, CARTAUD J, MULLER-ESTERL W, DUNIA I: Agonist-
induced redistribution of bradykinin B2 receptor in caveolae. J Cell
Sci 111:917–928, 1998
23. KIFOR O, DIAZ R, BUTTERS R, et al: The calcium-sensing receptor
is localized in caveolin-rich plasma membranes domains of bovine
parathyroid cells. J Biol Chem 273:21708–21713, 1998
24. LASLEY RD, NARAYAN P, UITTENBOGAARD A, SMART EJ: Activated
cardiac adenosine A1 receptors translocate out of caveolae. J Biol
Chem 275:4417–4421, 2000
25. GINES S, CIRUELA F, BURGUENO J, et al: Involvement of caveolin
in ligand-induced recruitment and internalization of A1 adenosine
receptor and adenosine deaminase in an epithelial cell line. Mol
Pharmacol 59:1314–1323, 2001
26. OKA N, ASAI K, KUDEJ RK, et al: Downregulation of caveolin by
chronic b-adrenergic receptor stimulation in mice. Am J Physiol
273:C1957–C1962, 1997
27. OSTROM R, GREGORIAN C, DRENAN RM, et al: Receptor number and
caveolar co-localization determine receptor coupling efficiency to
adenylyl cyclase. J Biol Chem 276:42063–42069, 2001
28. RYBIN VO, XU X, LISANTI MP, STEINBERG SF: Differential targeting
of b-adrenergic receptor subtypes and adenylyl cyclase to cardiomy-
ocyte caveolae. A mechanism to functionally regulate the cAMP
signaling pathway. J Biol Chem 275:41447–41457, 2000
29. FERON O, SMITH TW, MICHEL T, KELLY RA: Dynamic targeting of the
agonist-stimulated m2 muscarinic acetylcholine receptor to caveo-
lae in cardiac myocytes. J Biol Chem 272:17744–17748, 1997
30. NAVRATIL AM, BLISS SP, BERGHORN KA, et al: Constitutive local-
ization of the gonadotropin-releasing hormone (GnRH) receptor
to low density membrane microdomains is necessary for GnRH
signaling to ERK. J Biol Chem 278:31593–31602, 2003
31. OKAMOTO T, SCHLEGEL A, SCHERER PE, LISANTI MP: Caveolins, a
family of scaffolding proteins for organizing “preassembled signal-
ing complexes” at the plasma membranes. J Biol Chem 273:5419–
5422, 1998
32. CARMAN CV, BENOVIC JL: G-protein-coupled receptors: turn-ons
and turn-offs. Curr Opin Neurobiol 8:335–344, 1998
33. FERGUSON SS: Evolving concepts in G protein-coupled receptor en-
docytosis: The role in receptor desensitization and signaling. Phar-
macol Rev 53:1–24, 2001
34. SHENOY SK, MCDONALD PH, KOHOUT TA, LEFKOWITZ RJ: Regula-
tion of receptor fate by ubiquitination of activated b 2-adrenergic
receptor and b-arrestin. Science 294:1307–1313, 2001
35. JOSE PA, EISNER GM, FELDER RA: Dopamine receptor-coupling de-
fect in hypertension. Curr Hypertens Rep 4:237–244, 2002
36. SIBLEY DR: New insights into dopaminergic receptor function us-
ing antisense and genetically altered animals. Annu Rev Pharmacol
Toxicol 39:313–341, 1999
37. CLAING A, LAPORTE SA, CARON MG, LEFKOWITZ RJ: Endocytosis of
G protein-coupled receptors: Roles of G protein-coupled receptor
kinases and b-arrestin proteins. Prog Neurobiol 66:61–79, 2002
38. TIBERI M, NASH SR, BERTRAND L, et al: Differential regulation
of dopamine D1A receptor responsiveness by various G protein-
coupled receptor kinases. J Biol Chem 271:3771–3778, 1996
39. FELDER RA, SANADA H, XU J, et al: G protein-coupled receptor
kinase 4 gene variants in human essential hypertension. Proc Natl
Acad Sci USA 99:3872–3877, 2002
40. WATANABE H, XU J, BENGRA D, et al: Desensitization of human renal
D1 dopamine receptors by G protein-coupled receptor kinase 4.
Kidney Int 62:790–798, 2002
41. GARDNER B, LIU ZF, JIANG D, SIBLEY DR: The role of phosphory-
lation/dephosphorylation in agonist-induced desensitization of D1
dopamine receptor function: Evidence for a novel pathway for re-
ceptor dephosphorylation. Mol Pharmacol 59:310–321, 2001
42. NG GY, MOUILLAC B, GEORGE SR, et al: Desensitization, phospho-
rylation and palmitoylation of the human dopamine D1 receptor.
Eur J Pharmacol 267:7–19, 1994
43. VICKERY RG, VON ZASTROW M: Distinct dynamin-dependent and -
independent mechanisms target structurally homologous dopamine
receptors to different endocytic membranes. J Cell Biol 144:31–43,
1999
44. SCHEIFFELE P, VERKADE P, FRA AM, et al: Caveolin-1 and -2 in the
exocytic pathway of MDCK cells. J Cell Biol 140:795–806, 1998
45. MORA R, BONILHA VA, MARMORSTEIN A, et al: Caveolin-2 local-
izes to the Golgi complex but redistributes to plasma membrane,
caveolae, and rafts when co-expressed with caveolin-1. J Biol Chem
274:25708–25717, 1999
46. BRETON S, LISANTI MP, TYSZKOWSKI R, et al: Basolateral distribution
of caveolin-1 in the kidney. Absence from H+-ATPase-coated en-
docytic vesicles in intercalated cells. J Histochem Cytochem 46:205–
214, 1998
2180 Yu et al: Caveolin-2 regulation of the D1 receptor
47. XU J, LI XX, ALBRECHT FE, et al: Dopamine1 receptor, GSa, and
Na+-H+ exchanger interactions in the kidney in hypertension. Hy-
pertension 36:395–399, 2000
48. SUNAHARA RK, NIZNIK HB, WEINER, DM, et al: Human dopamine
D1 receptor encoded by an intronless gene on chromosome 5. Na-
ture 347:80–83, 1990
49. YU P, ASICO LD, EISNER GM, et al: Renal protein phosphatase 2A ac-
tivity and spontaneous hypertension in rats. Hypertension 36:1053–
1058, 2000
50. CHEN HT, BHANDOOLA A, DIFILIPPANTONIO MJ, et al: Response to
RAG-mediated VDJ cleavage by NBS1 and gamma-H2AX. Science
290:1962–1965, 2000
51. FELDER CC, CAMPBELL T, ALBRECHT F, JOSE PA: Dopamine inhibits
Na+-H+ exchanger activity in renal BBMV by stimulation of adeny-
late cyclase. Am J Physiol 259:F297–F303, 1990
52. BICKEL PE, SCHERER PE, SCHNITZER JE, et al: Flotillin and epidermal
surface antigen define a new family of caveolae-associated integral
membrane proteins. J Biol Chem 272:13793–13802, 1997
53. MORROW IC, REA S, MARTIN S, et al: Flotillin-1/reggie-2 traffics
to surface rafts domains via a novel Golgi-independent pathway.
Identification of a novel membrane targeting domain and a role for
palmitoylation. J Biol Chem 277:48834–48841, 2002
54. SALZER U, PROHASKA R: Stomatin, flotillin-1, and flotillin-2 are ma-
jor integral proteins of erythrocyte lipid rafts. Blood 97:1141–1143,
2001
55. VOLONTE D, GALBIATI F, LI S, et al: Flotillins/cavatellins are differ-
entially expressed in cells and tissues and form a hetero-oligomeric
complex with caveolins in vivo. Characterization and epitope-
mapping of a novel flotillin-1 monoclonal antibody probe. J Biol
Chem 274:12702–12709, 1999
56. FENG X, GAETA ML, MADGE LA, et al: Caveolin-1 associates with
TRAF2 to form a complex that is recruited to tumor necrosis factor
receptors. J Biol Chem 276:8341–8349, 2001
57. LI S, GALBIATI F, VOLONTE D, et al: Mutational analysis of
caveolin-induced vesicle formation. Expression of caveolin-1 re-
cruits caveolin-2 to caveolae membranes. FEBS Lett 434:127–134,
1998
58. SCHERER PE, LEWIS RY, VOLONTE D, et al: Cell-type and tissue-
specific expression of caveolin-2. Caveolins 1 and 2 co-localize
and form a stable hetero-oligomeric complex in vivo. J Biol Chem
272:29337–29346, 1997
59. FUJIMOTO T, KOGO H, ISHIGURO K, et al: Caveolin-2 is targeted to
lipid droplets, a new “membrane domain” in the cell. J Cell Biol
152:1079–1085, 2001
60. ECKERT GP, IGBAVBOA U, MULLER WE, WOOD WG: Lipid rafts of
purified mouse brain synaptosomes prepared with or without de-
tergent reveal different lipid and protein domains. Brain Research
962:144–150, 2003
61. VENTURA AL, SIBLEY DR: Altered regulation of the D1 dopamine
receptor in mutant Chinese hamster ovary cells deficient in cyclic
AMP-dependent protein kinase activity. J Pharmacol Exp Ther
293:426–434, 2000
62. MASON JN, KOZELL LB, NEVE KA: Regulation of dopamine D1 re-
ceptor trafficking by protein kinase A-dependent phosphorylation.
Mol Pharmacol 61:806–816, 2002
63. ALBRECHT FE, XU J, MOE OW, et al: A Regulation of NHE3 ac-
tivity by G protein subunits in renal brush-border membranes. Am
J Physiol Regulatory Integrative Comp Physiol 278:R1064–R1073,
2000
64. DANIEL PB, WALKER WH, HABENER JF: Cyclic AMP signaling and
gene regulation. Annu Rev Nutr 18:353–383, 1998
65. YAMAGUCHI I, WALK SF, FELDER RA: Studying the dopaminergic
system with transfected receptors. Hypertens Res 18(Suppl):S19–
S22, 1995
66. GINGRICH JA, DEARRY A, FALARDEAU P, et al: Location and molecu-
lar cloning of D1 dopamine receptor. Neurochem Int 20 (Suppl):9S–
15S, 1992
67. JARVIE KR, BOOTH G, BROWN EM, NIZNIK HB: Glycoprotein nature
of dopamine D1 receptors in the brain and parathyroid gland. Mol
Pharmacol 36:566–574, 1989
68. JACKSON A, IWASIOW RM, CHAAR ZY, et al: Homologous regu-
lation of the heptahelical D1A receptor responsiveness: Specific
cytoplasmic tail regions mediate dopamine-induced phosphory-
lation, desensitization and endocytosis. J Neurochem 82:683–697,
2002
69. LEVEY AI, HERSCH SM, RYE DB, et al: Localization of D1 and D2
dopamine receptors in brain with subtype-specific antibodies. Proc
Natl Acad Sci USA 90:8861–8865, 1993
70. SHEFF D, PELLETIER L, O’CONNELL CB, et al: Transferrin receptor
recycling in the absence of perinuclear recycling endosomes. J Cell
Biol 156:797–804, 2002
71. MCCAFFREY MW, BIELLI A, CANTALUPO G, et al: Rab4 affects both
recycling and degradative endosomal trafficking. FEBS Lett 495:21–
30, 2001
